DOW JONES23,433.57+779.71 3.44%
S&P 5002,749.98+90.57 3.41%
NASDAQ8,090.90+203.64 2.58%

Morgan Stanley Downgrades Nabriva Therapeutics to Equal-Weight, Lowers Price Target to $2

Morgan Stanley analyst David Lebowitz downgrades Nabriva Therapeutics (NASDAQ:NBRV) from Overweight to Equal-Weight and lowers the price target from $7 to $2.

Benzinga · 03/17/2020 13:19

Morgan Stanley analyst David Lebowitz downgrades Nabriva Therapeutics (NASDAQ:NBRV) from Overweight to Equal-Weight and lowers the price target from $7 to $2.